BioCryst currently has two novel late-stage development programs: peramivir, a viral neuraminidase inhibitor for the treatment of influenza, BCX4208, a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout. In addition, BioCryst has two preclinical programs advancing towards IND filings: BCX5191, a nucleoside analog inhibitor of HCV RNA polymerase (NS5B) for hepatitis C, and BCX4161, an oral inhibitor of plasma kallikrein for hereditary angioedema.

Peramivir Outpatient Flu 1 (SEASONAL INFLUENZA / I.V.)

Peramivir Hospitalized Flu (ACUTE INFLUENZA / I.V.)

BCX5191 (HEPATITIS C)

BCX4208(GOUT)

BCX4161 (HEREDITARY ANGIOEDEMA)

Forodesine 2

¹ Peramivir is approved in Japan & Korea.
² Forodesine is being developed under a global license agreement by Mundipharma International Limited.